Literature DB >> 15175042

Chromosomal aberration patterns differ in subtypes of primary cutaneous B cell lymphomas.

Christian Hallermann1, Kjell M Kaune, Reiner Siebert, Maarten H Vermeer, Cees P Tensen, Rein Willemze, Bastian Gunawan, Hans Peter Bertsch, Christine Neumann.   

Abstract

The diagnostic and prognostic importance of recurrent chromosomal aberrations in systemic B cell lymphoma is well documented. In contrast, limited data exist on genetic changes in primary cutaneous B cell lymphoma. In this study we investigated chromosomal aberration patterns in two types of primary cutaneous B cell lymphoma with a different clinical behavior. Twenty-two primary cutaneous B cell lymphomas, including nine follicle center cell lymphomas and 13 large B cell lymphomas of the leg, were analyzed by comparative genomic hybridization and in part by fluorescence in situ hybridization. The most frequent imbalances detectable were gains in 18q (eight of 22), 1q (six of 22), 7 (six of 22), 12q (six of 22), or Xp (four of 22), and losses in 6q (four of 22). In contrast to large B cell lymphomas of the leg, primary cutaneous follicle center cell lymphomas had fewer imbalances and lacked translocations affecting the IGH locus. Gains in 18q (eight of 13) and losses in 6q (four of 13) as well as breakpoints within the IGH locus (six of 11) were restricted to the large B cell lymphomas of the leg subtype. Translocation t(14; 18) was excluded in 16 primary cutaneous B cell lymphomas of both subtypes that were studied by fluorescence in situ hybridization. These results suggest that primary cutaneous follicle center cell lymphoma and large B cell lymphoma of the leg are characterized by different chromosomal aberration patterns, which in part might determine the different clinical course of these malignancies.

Entities:  

Mesh:

Year:  2004        PMID: 15175042     DOI: 10.1111/j.0022-202X.2003.12635.x

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  8 in total

1.  [Malignant lymphoma of the skin: update on diagnostics and therapy of primary cutaneous B-cell lymphoma].

Authors:  C Hallermann; C Niermann; M Fluck; A-R Fischedick; H-J Schulze
Journal:  Hautarzt       Date:  2011-12       Impact factor: 0.751

Review 2.  [Immunohistochemical and molecular-pathologic investigations in dermatohistology].

Authors:  M J Flaig; U Puchta; C A Sander
Journal:  Hautarzt       Date:  2007-09       Impact factor: 0.751

Review 3.  [Aggressive primary cutaneous B-cell lymphomas and novel EBV+ entities].

Authors:  C Lamos; E Dippel
Journal:  Hautarzt       Date:  2017-09       Impact factor: 0.751

4.  Inactivation of p16INK4a/CDKN2A gene may be a diagnostic feature of large B cell lymphoma leg type among cutaneous B cell lymphomas.

Authors:  Marc-Antoine Belaud-Rotureau; Virginie Marietta; Beatrice Vergier; Guillaume Mainhaguiet; Michelle Turmo; Yamina Idrissi; Jacky Ferrer; Marie Beylot-Barry; Pierre Dubus; Jean-Philippe Merlio
Journal:  Virchows Arch       Date:  2008-03-01       Impact factor: 4.064

Review 5.  Update on extranodal lymphomas. Conclusions of the Workshop held by the EAHP and the SH in Thessaloniki, Greece.

Authors:  E Campo; A Chott; M C Kinney; L Leoncini; C J L M Meijer; C S Papadimitriou; M A Piris; H Stein; S H Swerdlow
Journal:  Histopathology       Date:  2006-04       Impact factor: 5.087

6.  A Literature Revision in Primary Cutaneous B-cell Lymphoma.

Authors:  R La Selva; S Alberti Violetti; C Delfino; V Grandi; S Cicchelli; C Tomasini; M T Fierro; E Berti; N Pimpinelli; P Quaglino
Journal:  Indian J Dermatol       Date:  2017 Mar-Apr       Impact factor: 1.494

Review 7.  Primary Cutaneous B-Cell Lymphomas: An Update.

Authors:  Paola Vitiello; Antonello Sica; Andrea Ronchi; Stefano Caccavale; Renato Franco; Giuseppe Argenziano
Journal:  Front Oncol       Date:  2020-05-27       Impact factor: 6.244

8.  The role of molecular pathology in the diagnosis of cutaneous lymphomas.

Authors:  Philipp W Raess; Adam Bagg
Journal:  Patholog Res Int       Date:  2012-11-19
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.